vidence of rapidly rising levels of obesity has led to increasing concerns about the effect of diet on health, both globally and in Europe. [1] [2] [3] [4] Diet is implicated in many major western diseases, such as ischaemic heart disease (IHD), stroke, some cancers and type 2 diabetes. 1 3 In the UK, it is estimated that 10% of all disability-adjusted life years lost can be attributed to poor diet. 5 Changes in diet, such as reductions in the intake of fat, particularly saturated fat, and sodium, have been advocated to reduce the incidence of some of these diseases. [6] [7] [8] A variety of approaches have been advocated, including altering the price of food. 3 9 In the UK, there have been calls for taxation on food to improve health, often termed a fat tax, 9 and a recent Parliamentary Select Committee recommended that ''the Government should keep an open mind on this issue''. 2 At a European level, the European Heart Network has called for a comprehensive and integrated food policy, which includes a pricing strategy. 10 The World Health Organization recognises that the pricing of healthy food is important for improving diet in order to prevent diseases. 3 Taxation to increase price and reduce consumption has been an important part of reducing tobacco consumption in order to improve health in the UK. 11 12 Increasing tax on alcohol is also an effective means to reduce consumption. 13 However, there are important differences between tobacco, or alcohol, and food. The success of any fat tax depends on changes in foodpurchasing patterns with the outcome of a healthier diet. A healthier diet could improve health by a variety of means-for example, reducing serum cholesterol to reduce the incidence of cardiovascular disease. A recent literature review found a wide variety of taxes levied on food, but that the intention normally was to raise revenue rather than to change diet and improve health. 9 Moreover, there was little information on the effects of food taxes on behaviour and health to inform the ongoing debate on a fat tax. Only one paper, by Marshall, 14 was identified which attempted to estimate the effects of extending value added tax (VAT) to products high in saturated fat on health. Like others, we also feel that extending VAT to additional food categories might be the preferred means for legislators to introduce a targeted food tax to improve health. 14 15 Currently, in the UK, VAT at the standard rate of 17.5% is charged on a range of different foods including confectionery, ice cream, savoury snacks and most drinks, foods typically sold by catering outlets. Using empirical economic and dietary data, together with estimates of the effect of diet on health, we sought to estimate the potential health and dietary effects of extending VAT in the UK to additional categories of food.
METHODS
We used empirical economic data to predict the effect of a rise in price (by 17.5%, the current UK rate of VAT) on changes in consumption. The own price elasticity of demand predicts the percentage change in consumption (quantity brought) of that item for a 1% rise in price: for example, if the price elasticity of bread is -0.40, a 10% rise in the price of bread, all other things being equal, will result in a fall in consumption of bread by 4%. In addition, if the price of bread rises, the consumption of margarine may fall. The cross-price elasticity of demand predicts this effect. For example, a cross-price elasticity of -0.1 for margarine with respect to the price of bread means that for a 10% rise in the price of bread the consumption of margarine would fall by 1%. Typically, items that complement each other have a negative cross-elasticity, while items that can be substituted have a positive cross-elasticity. For each item of food taxed, the effect on consumption is calculated using each item's own price elasticity of demand. In addition, the effect on consumption of other items is calculated using the appropriate cross-price elasticity value. We assumed that changes in consumption (quantity purchased) led to changes in what was actually eaten. We then estimated the effect of changes in nutritional intake, changes in salt intake and the intake of Abbreviations: IHD, ischaemic heart disease; VAT, value added tax different types of fat (by their effect on serum cholesterol), on mortality from cardiovascular disease (both strokes and IHD), using empirical data derived from meta-analyses.
As there were many calculations to make for any item on which VAT was introduced, in order to predict the effect on diet and health, the calculations were performed using a spreadsheet model (Microsoft Excel 2000) . Within this model, it is possible to alter taxed food items and observe the effect on a range of health and diet outcomes. The different configurations of food items taxed were termed ''approaches''. The three approaches we investigated were the following.
Saturated fat
Marshall proposed extending VAT to the main sources of dietary saturated fats (whole milk, butter, cakes and pastries, biscuits, puddings and ice creams, cheese and buns). 14 We replicated Marshall's proposal as best we could with the categories provided by our data.
SSCg3d
SSCg3d scores are a quantitative estimate of how unhealthy a food is. 16 Eight nutritional parameters determine the food's score. Points (up to a maximum of 10) are scored for energy density, saturated fat, sodium and non-milk extrinsic sugar and subtracted for fruit and vegetable content, iron, calcium and n-3 polyunsaturated fat. Scores range from 212 (spinach) to +29 (chocolate digestive biscuits). We applied VAT to all foods classified as less healthy by this model (ie, foods with a SSCg3d score of >9).
Best outcome
We sought to establish the maximum potential gain with a taxation level of 17.5%, while trying to minimise the additional cost to the consumer. We used the model to test the effect of taxing different food items on the following outcomes: reduction in serum cholesterol by changes in dietary fat; reduction in salt, non-milk extrinsic sugar and calorie intake; increase in fruit and vegetable consumption. By judicious use of trial and error, we sought to identify the configuration of taxed items that maximised these outcomes, which we call best outcome. Table 1 shows which food categories, taken from the National Food Survey, 17 are taxed in each model, together with their SSCg3d scores.
DATA
We took data for food consumption, expenditure and elasticity values from the National Food Survey 2000. 17 The National Food Survey was an annual survey using interviews and diaries to record food bought for consumption at home in Great Britain. The National Food Survey for 2000 suggested that food and drink consumed outside the home was responsible for 26% of expenditure (excluding alcohol). Therefore, we assumed that food bought for consumption at home represents about 75% of total food consumption by energy, and that food consumption outside the home is not affected by the tax changes examined. The National Food Survey categorises foods into groups (table 1) . Because the subcategory items are similar, we assumed firstly the own price elasticity to be the same as the main category of which it is a member, and secondly the crossprice elasticities between subcategories to be 0.6 (similar items are relatively substitutable: eg, butter or margarine). This was subjected to sensitivity analysis.
We took estimates of the effect of changes in intake of dietary fat and cholesterol on serum cholesterol from a quantitative meta-analysis of metabolic ward studies, shown in table 2. 6 We estimated the effect of serum cholesterol on mortality from IHD by two means: first, using the summary data from a metaanalysis of 58 randomised trials of cholesterol-lowering by any means and IHD events, which predicts that a 1.6 mmol/l reduction in low-density lipoprotein would cause a fall in IHD by around 50% 18 ; second, using the method employed by Sacks and Katan. 19 Their estimates are based on four large prospective American studies [20] [21] [22] [23] [24] and assume that a 1 mg/dl reduction in low-density lipoprotein reduces IHD by 1% 25 and that a 1 mg/dl increase in serum high-density lipoprotein cholesterol reduces IHD by 2% in men and by 3% in women. 26 Marshall used a similar method, but relied on older data 7 together with Clarke's estimates. 6 We did not consider the relationship between serum cholesterol and fatal cerebrovascular disease, because this is less well established. 18 27 28 We used data derived from a quantitative meta-analysis, shown in table 3, to estimate the effect of salt intake on mortality from stroke and IHD. 8 We took data from the British Heart Foundation's statistical database (www.heartstats.org.uk) for estimates of the number of deaths from cardiovascular disease in the UK, for 2003. Table 4 shows results from the three taxation regimens examined, comparing expenditure, nutrient intake and effects on cardiovascular disease. In addition, the table shows the results previously obtained by Marshall in his analysis of a fat tax. Both models taxed a similar proportion of dietary saturated fat. The change in dietary saturated fat intake predicted by our model is about half that predicted by Marshall, and with changes in other fats considered, noticeably a rise in serum cholesterol from a fall in polyunsaturated fat, shown in table 5, the net effect on serum cholesterol is negligible. Our saturated fat estimate suggested that such a tax could cause a small rise in salt intake, as a result of cross-price elasticities of demand, and might overall result in more deaths than it averts. Sensitivity analysis showed that the magnitude of this effect is dependent on the cross-price elasticity between subcategory items, and varies from 1800 to 4000 extra deaths, depending on the cross-price elasticity chosen between 0 and 1. If the effect of salt intake on cardiovascular disease was half of the lower estimate of He and MacGregor 8 , then the number of extra deaths would fall to between 1300 and 1900.
RESULTS
Our second estimate, taxing items with a high SSCg3d score, predicted a small increase in serum cholesterol. However, overall the SSCg3d estimate predicted a reduction in deaths, due to cardiovascular disease, of between 2100 and 2500 every year, primarily owing to a substantial reduction in salt intake. Our best outcome estimate predicted a reduction of between 2600 to 3200 cardiovascular disease deaths every year, again largely by reducing salt intake. These estimates of number of lives saved were not strongly affected by altering the withincategory cross-price elasticity value between 0 and 1 (ranging from 1900 to 2700 for SSCg3d, and from 2600 to 3200 for best outcome. If the effect of salt intake on cardiovascular disease was half of the lower estimate of He and MacGregor, 8 then the number of lives saved would be 700 for SSCg3d and 1100 for best outcome.
All three taxation estimates predicted a fall in fruit and vegetable consumption of approximately 2-4%, again as a result of cross-elasticity effects. The saturated fat tax would increase weekly household food expenditure by approximately 3.2%, the SSCg3d tax would increase expenditure by 4%, and the best outcome approach would increase expenditure by 4.6%, equivalent to an extra 67 pence per person per week or approximately £2 billion annually across the UK (2000 prices).
DISCUSSION
Our estimate of the effect on cardiovascular disease of introducing taxes on the major sources of dietary fat is significantly different from that reported previously by Marshall. 14 The change in dietary saturated fat intake that we predicted would result from such a fat tax is smaller than Marshall predicted. Marshall's work had a number of limitations. Firstly, it used the author's own estimates of the effect of taxation on the consumption of food, rather than empirically obtained values. The empirical elasticity values are less than his estimates and the empirical data suggest there will be greater substitution with other high-fat products than he predicted. Secondly, the analysis was restricted to saturated fat and did not take account of the impact of a tax on the intake of other nutrients, such as polyunsaturated fat and salt. Our model suggests that beneficial reductions in saturated fat are partly offset by reductions in polyunsaturated and monounsaturated fat and that a small rise in salt intake from such a tax would have a detrimental effect on mortality from cardiovascular disease.
The cross-elasticity effects show that food consumption is highly interdependent and difficult to predict. Our model suggests that there could be a variety of unintended potentially detrimental effects, caused by the estimated cross-price elasticities of demand. For example, we observed that reducing saturated fat consumption tended to increase salt consumption and that fruit consumption tended to fall as a result of taxation on milk and cream.
When designing the best outcome taxation strategy, we found it hard to achieve a reduction in serum cholesterol: when taxing broad categories of foods, if the intake of saturated fat is reduced the intake of other fats such as polyunsaturates and monounsaturates is also reduced. The reduction in intake of polyunsaturates and monounsaturates causes a rise in serum cholesterol that counters the fall achieved from the reduction in saturated fat. In addition, we observed a trade off between the reduction in the proportion of energy derived from saturated fat and a reduction in salt intake; some food products high in salt, such as some cereal products, also tend to be high in sugar and therefore energy dense; so reducing salt intake reduces non-fat calorie intake, increasing the proportion of energy derived from saturated fat, which tends to increase serum cholesterol. The additional benefit gained from taxing items outside the least healthy category was small. Moreover, as the more healthy food items were taxed, in addition to the less healthy food items (ie, extending VAT to nearly all food items), the potential number of lives saved tended to fall slightly and a further reduction in fruit and vegetable consumption was observed. Further gains would best be achieved by a higher rate of taxation on least healthy food items, rather than extending the VAT at 17.5% to healthier food items. Food consumption is relatively insensitive to price changes, such that a taxation rate of 17.5% is likely to reduce the intake of nutrients such as salt and saturated fats by no more than 5-10%. So the scope for significantly altering the national diet by judicious use of VAT seems limited. Greater change could be achieved with a higher level of taxation, but this is unlikely for political and economic reasons. To achieve large changes, such as 3-6 g per day reduction in salt intake 8 or 0.60 mmol/l reduction in serum cholesterol, 7 which have been advocated, it may be necessary for the food industry to produce foods with less salt and less saturated fat. Rose argued that small changes in risk factors for diseases of high prevalence can produce meaningful change at a population level, 29 and our results suggest that, although the percentage changes in the incidence of cardiovascular disease are small, the actual number of lives saved could be substantial because of the high incidence of cardiovascular disease in the UK. Fat taxes would not eliminate dietary-related diseases, but could be one of several tools used to achieve that goal.
Our data should be interpreted cautiously. Firstly, our estimates of the effect of targeted food taxes on the number of deaths are crude and limited to the effects of dietary fat and salt on cardiovascular disease; they give only a rough guide to the magnitude of the effects that we may see. We have not looked at the effect of other nutrients on health, which are not well characterised; about one third of the cancer mortality could be related to diet. 7 Secondly, the model assumes that all food purchased for consumption at home is eaten: we make no allowance for the proportion of food that is not eaten, but discarded. We have also assumed that food eaten outside the home is unaffected by the taxation. Thirdly, the food categories used in the model contain a wide range of products, and it may not be reasonable to assume that all products within each category will behave in the same way: our experience, from using the model, suggests that better targeting of taxation to smaller more precise food categories produces better results. Fourthly, the relationships between price changes and changes in health have been captured using aggregate population data. A variety of factors other than price influence individual food purchase behaviour, including the palatability of foods, attitudes to and knowledge about foods, and some of these factors are captured in price elasticity of demand. Similarly, a variety of factors other than diet, such as age, sex and lifestyle factors, like smoking, influence health. A more complex model could in theory incorporate these factors. Fifth, our elasticity data are based on the UK population, so making predictions for other countries, particularly with respect to possible cross-price elasticity effects, may be inappropriate. Other approaches to fat taxes, such as taxes on specific ingredients such as salt or added sugar, are beyond the scope of this paper. The type of fat tax we have modelled in this study could be portrayed as a restriction on personal freedom. However, it could also be considered as a counterweight to other market influences, such as advertising, that affect our choice of food and the associated health benefits and harms.
One common criticism of fat taxes is that they are regressive-that is, that low-income households would pay a greater percentage of their income on fat taxes than higherincome households. 30 An analysis of the effects on different income groups was not possible using our model, because the National Food Survey does not provide price elasticity data split by economic group. However, theoretically, those on low incomes should be more price sensitive in their pattern of demand and therefore may be more likely to change their consumption patterns and obtain larger proportional health benefit, as seems to happens with cigarette consumption. 11 
CONCLUSIONS
The factors that affect food consumption patterns are highly interdependent, and careful consideration of unintended crosselasticity effects and changes across a range of nutrients need to be considered when assessing the effect of any fat tax. The potential changes in nutrition that would result from an extension of VAT to further categories of food are modest. However, given the high incidence of cardiovascular disease and the acknowledged contributory role of dietary salt and fat, inducing even small changes in diet has the potential to produce worthwhile population level changes in its incidence. A well-designed and carefully targeted fat tax could be a useful tool for reducing the burden of food-related disease.
What this paper adds
Fat taxes may be used to produce modest changes in diet, which at a population level would have a meaningful effect on mortality. More research is needed to better understand the potential effects of any fat tax, particularly the effect on the poor.
Policy implications
Fat taxes could be used, by governments to improve national diet and reduce the incidence of diet-related disease. Careful consideration needs to be given to designing fat taxes, examining the effect of any taxation on a range of nutrients.
What is already known N Fat taxes have been proposed to alter consumption patterns and reduce the incidence of diet-related disease.
N Fat taxes will be regressive and resisted by the food industry. Most taxes levied on food are aimed at raising revenue, and the effect on health is uncertain.
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